Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196410 | 1.00 | RIPK1 (0.37) | RIPK1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2197629 | 0.85 | KDM4E (0.43) | RIPK1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2202724 | 0.84 | ALOX5 (0.43) | RIPK1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2239284 | 0.83 | PPARA (0.41) | RIPK1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2107176 | 0.83 | PPARA (0.41) | RIPK1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2198620 | 0.82 | ADRB2 (0.44) | KDM4EMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2196598 | 0.82 | ADRB2 (0.48) | KDM4EMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL2200379 | 0.82 | ADRB2 (0.44) | KDM4EMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2429212 | 0.80 | ESR1 (0.42) | LMNACYP3A4ALOX5 | |
| SCHEMBL1448846 | 0.80 | ESR1 (0.42) | LMNACYP3A4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | RIPK1 1680/4885KDM4E 1233/4885MEN1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.